FDA launches comprehensive review of rare disease drug approval process
The U.S. Food and Drug Administration is initiating a top-to-bottom review of its rare disease drug development and approval framework, aiming to standardize its approach to scientific evidence and prioritize consistency over flexibility. The new framework seeks to reduce uncertainty for investors and bring rare disease therapies to patients faster.
